Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

Returns on capital

Pharming Group N.V. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

1.0%

avg -41.3%

ROIC

1.0%

avg -52.7%

ROA

0.6%

avg -2.4%

Analysis

ROIC is currently the strongest return metric at 1.0% versus its period average of -52.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Fabrice Chouraqui

Chief Executive Officer & Executive DirectorEUR 1.84M———

Bruno L. Giannetti

Consultant—74——

Alexander Breidenbach

Chief Business Officer—63——

Magnus Hansson

Medical Director—50——

Kenneth Lynard EMBA

CFO & Co-Chief Executive Officer—58——

Michael Levitan

Vice President of Investor Relations & Corporate Communications————

Ruud Van Outersterp

Chief Legal & Compliance Officer and Company Secretary—62——

Ines Bernal

Chief People Officer————

Leverne Marsh

Co-CEO & Chief Commercial Officer————

Mireille Sanders

Chief Operations Officer—58——

Anurag Relan

Chief Medical Officer—54——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A-37.0%
+69.5% (5yr)1 analysts
RevenueN/AN/A+22.4%
+11.2% (5yr)2 analysts
Net IncomeN/AN/A-40.6%
+69.4% (5yr)2 analysts
EBITN/AN/A+4.6%
+24.5% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +22.4% over three years. Forward estimates point to EPS at +69.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Pharming Group N.V. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PHAR's management, answered from reported figures.

Who manages PHAR?

Pharming Group N.V. (PHAR) lists 11 active executives. The top listed executive is Bruno L. Giannetti, Consultant.

Are PHAR insiders buying or selling?

Recent insider activity shows net buying of $3,400.00.